Comparison of drug-releasing stents show similar safety outcomes after two years

March 31, 2014

A comparison of the safety of biodegradable polymer biolimus-eluting stents vs durable polymer everolimus-eluting stents finds similar outcomes for measures including death and heart attack after two years, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions.

Recent studies have raised concerns about the of drug-eluting stents (BP-DES) compared with durable polymer everolimus-eluting stents (DP-EES). The NOBORI Biolimus-Eluting vs XIENCE/PROMUS Everolimus-Eluting Stent Trial (NEXT) is a study evaluating the efficacy and safety of biodegradable polymer biolimus-eluting stents (BP-BES) vs. DP-EES. The primary efficacy outcome of target-lesion revascularization (restoration of blood flow in coronary arteries) at 1 year demonstrated noninferiority (not worse than) of BP-BES compared with DP-EES. However, the advantages of BP-BES could emerge beyond 1 year when polymer has fully degraded, according to background information in the article. Masahiro Natsuaki, M.D., of Saiseikai Fukuoka General Hospital, Fukuoka, Japan, and colleagues examined outcomes of this trial after two years.

Of 3,235 patients, 1,617 were randomly assigned to receive BP-BES and 1,618 to DP-EES. The researchers found that treatment outcomes with BP-BES were noninferior to DP-EES for death or heart attack (7.8 percent vs 7.7 percent, respectively) and target-lesion revascularization (TLR) (6.2 percent vs 6.0 percent). The rates of or and TLR were not significantly different between the groups at 2 years.

"In NEXT, the safety and efficacy outcomes of BP-BES were noninferior to those of DP-EES at 2 years. However, 2 years is not long enough to confirm the long-term safety of BP-BES, and the study was underpowered for the interim analysis. Follow-up at 3 years will be important," the authors write.

More information: DOI: 10.1001/jama.2014.3584

Related Stories

Drug-Eluting stents reduce risk of thrombosis

March 23, 2012

(HealthDay) -- Cobalt-chromium everolimus eluting stents (CoCr-EES) are associated with a significantly lower rate of stent thrombosis within two years of implantation, compared with other bare-metal and drug-eluting stents, ...

New biolimus stent equal to everolimus stent at one year

March 11, 2013

In a match-up of Japan's top drug-releasing stent and a new device featuring a biodegradable coating, the newcomer delivered statistically comparable one-year results, according to data from the NEXT trial presented today ...

Results of the SORT-OUT VI trial presented

October 30, 2013

A new study found that both drug-eluting stents (DES) with biocompatible polymers and DES with biodegradable polymers were associated with low major adverse coronary events, demonstrating the non-inferiority of the biocompatible ...

Recommended for you

Heart attack treatment hypothesis 'busted'

July 6, 2015

Researchers have long had reason to hope that blocking the flow of calcium into the mitochondria of heart and brain cells could be one way to prevent damage caused by heart attacks and strokes. But in a study of mice engineered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.